Locoregional MYCN-amplified neuroblastoma
Por:
Morales-La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E and Cohn SL
Publicada:
1 oct 2012
Ahead of Print:
1 ene 2012
Resumen:
MYCN-amplification is strongly associated with other high-risk prognostic factors and poor outcome in neuroblastoma. Infrequently, amplification of MYCN has been identified in localized tumors with favorable biologic features. Outcome for these children is difficult to predict and optimal treatment strategies remain unclear. We report a 5-month-old who presented with an MYCN-amplified INSS stage 3, pelvic neuroblastoma. The tumor had favorable histology, hyperdiploidy, and lacked 1p36 and 11q23 aberrations. Although the patient met the criteria for high-risk neuroblastoma, because of the discordant prognostic markers we elected to treat her according to an intermediate-risk protocol. She remains event-free more than 18 months.
FULL TEXT
 |
Submitted Version |
https://www.wiley.com/en-us/network/publishing/research-publishing/open-access/copyright-and-licensing-with-wiley |
|
|